T. Shathasivam, T. Kislinger, A.O. Gramolini, Genes, proteins and complexes: the multifaceted nature of FHL family proteins in diverse tissues. J. Cell Mol. Med. 14, 2702–2720 (2010)

Article  PubMed  PubMed Central  CAS  Google Scholar 

X. Cai, J. Wang, X. Huang, W. Fu, W. Xia, M. Zou et al. Identification and characterization of MT-1X as a novel FHL3-binding partner. PLoS One 9, e93723 (2014)

Article  PubMed  PubMed Central  Google Scholar 

J. Lin, L. Ding, R. Jin, H. Zhang, L. Cheng, X. Qin et al. Four and a half LIM domains 1 (FHL1) and receptor interacting protein of 140kDa (RIP140) interact and cooperate in estrogen signaling. Int. J. Biochem. Cell Biol. 41, 1613–1618 (2009)

Article  PubMed  CAS  Google Scholar 

B.S. Cowling, M.J. McGrath, M.A. Nguyen, D.L. Cottle, A.J. Kee, S. Brown et al. Identification of FHL1 as a regulator of skeletal muscle mass: implications for human myopathy. J. Cell Biol. 183, 1033–1048 (2008)

Article  PubMed  PubMed Central  CAS  Google Scholar 

J. Schessl, S. Feldkirchner, C. Kubny, B. Schoser, Reducing body myopathy and other FHL1-related muscular disorders. Semin. Pediatr. Neurol. 18, 257–263 (2011)

Article  PubMed  Google Scholar 

Y. Liu, C. Wang, P. Cheng, S. Zhang, W. Zhou, Y. Xu et al. FHL1 inhibits the progression of colorectal cancer by regulating the Wnt/β-catenin signaling pathway. J. Cancer 12, 5345–5354 (2021)

Article  PubMed  PubMed Central  CAS  Google Scholar 

C. Niu, C. Liang, J. Guo, L. Cheng, H. Zhang, X. Qin et al. Downregulation and growth inhibitory role of FHL1 in lung cancer. Int. J. Cancer 130, 2549–2556 (2012)

Article  PubMed  CAS  Google Scholar 

L. Ding, C. Niu, Y. Zheng, Z. Xiong, Y. Liu, J. Lin et al. FHL1 interacts with oestrogen receptors and regulates breast cancer cell growth. J. Cell Mol. Med. 15, 72–85 (2011)

Article  PubMed  CAS  Google Scholar 

Y. Xu, Z. Liu, K. Guo, Expression of FHL1 in gastric cancer tissue and its correlation with the invasion and metastasis of gastric cancer. Mol. Cell Biochem. 363, 93–99 (2012)

Article  PubMed  CAS  Google Scholar 

J. Wang, F. Huang, J. Huang, J. Kong, S. Liu, J. Jin, Epigenetic analysis of FHL1 tumor suppressor gene in human liver cancer. Oncol. Lett. 14, 6109–6116 (2017)

PubMed  PubMed Central  Google Scholar 

Y. Liu, H. Li, Y. Zhao, D. Li, Q. Zhang, J. Fu et al. Targeting FHL1 impairs cell proliferation and differentiation of acute myeloid leukemia cells. Biochem. Cell Biol. 100, 301–308 (2022)

Article  PubMed  CAS  Google Scholar 

C. Wang, X. Lv, C. He, J.S. Davis, C. Wang, G. Hua, Four and a Half LIM Domains 2 (FHL2) Contribute to the Epithelial Ovarian Cancer Carcinogenesis. Int. J. Mol. Sci. 21, 7751 (2020)

Article  PubMed  PubMed Central  CAS  Google Scholar 

W. Zhang, J. Wang, B. Zou, C. Sardet, J. Li, C.S. Lam et al. Four and a half LIM protein 2 (FHL2) negatively regulates the transcription of E-cadherin through interaction with Snail1. Eur. J. Cancer 47, 121–130 (2011)

Article  PubMed  CAS  Google Scholar 

E. Zienert, I. Eke, D. Aust, N. Cordes, LIM-only protein FHL2 critically determines survival and radioresistance of pancreatic cancer cells. Cancer Lett. 364, 17–24 (2015)

Article  PubMed  CAS  Google Scholar 

L. Qiao, Y. Wang, R. Pang, J. Wang, Y. Dai, J. Ma et al. Oncogene functions of FHL2 are independent from NF-kappaBIalpha in gastrointestinal cancer. Pathol. Oncol. Res. 15, 31–36 (2009)

Article  PubMed  CAS  Google Scholar 

Y. Nouët, J. Dahan, C. Labalette, F. Levillayer, B. Julien, G. Jouvion et al. The four and a half LIM-only protein 2 regulates liver homeostasis and contributes to carcinogenesis. J. Hepatol. 57, 1029–1036 (2012)

Article  PubMed  Google Scholar 

G. Cao, P. Li, X. He, M. Jin, M. Li, S. Chen et al. FHL3 contributes to EMT and chemotherapy resistance through up-regulation of slug and activation of TGFβ/Smad-independent pathways in gastric cancer. Front. Oncol. 11, 649029 (2021)

Article  PubMed  PubMed Central  CAS  Google Scholar 

P. Li, G. Cao, Y. Zhang, J. Shi, K. Cai, L. Zhen et al. FHL3 promotes pancreatic cancer invasion and metastasis through preventing the ubiquitination degradation of EMT associated transcription factors. Aging (Albany NY) 12, 53–69 (2020)

Article  PubMed  CAS  Google Scholar 

C. Niu, Z. Yan, L. Cheng, J. Zhu, H. Zhang, X. Xu et al. Downregulation and antiproliferative role of FHL3 in breast cancer. IUBMB Life 63, 764–771 (2011)

Article  PubMed  CAS  Google Scholar 

C.M. Kitahara, J.A. Sosa, The changing incidence of thyroid cancer. Nat. Rev. Endocrinol. 12, 646–653 (2016)

Article  PubMed  PubMed Central  Google Scholar 

S.R. Chung, J.H. Baek, Y.J. Choi, J.H. Lee, Longer-term outcomes of radiofrequency ablation for locally recurrent papillary thyroid cancer. Eur. Radio. 29, 4897–4903 (2019)

Article  Google Scholar 

S. Ulisse, E. Baldini, A. Lauro, D. Pironi, D. Tripodi, E. Lori et al. Papillary thyroid cancer prognosis: an evolving field. Cancers (Basel) 13, 5567 (2021)

Article  PubMed  CAS  Google Scholar 

M.A. Adam, J. Pura, L. Gu, M.A. Dinan, D.S. Tyler, S.D. Reed et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann. Surg. 260, 601–605 (2014).

Article  PubMed  Google Scholar 

J.S. Radowsky, R.S. Howard, H.B. Burch, A. Stojadinovic, Impact of degree of extrathyroidal extension of disease on papillary thyroid cancer outcome. Thyroid 24, 241–244 (2014)

Article  PubMed  Google Scholar 

R. Nusse, H. Clevers, Wnt/β-catenin signaling, disease, and emerging therapeutic modalities. Cell 169, 985–999 (2017)

Article  PubMed  CAS  Google Scholar 

Y. Zhang, X. Wang, Targeting the Wnt/β-catenin signaling pathway in cancer. J. Hematol. Oncol. 13, 165 (2020)

Article  PubMed  PubMed Central  Google Scholar 

T. Valenta, G. Hausmann, K. Basler, The many faces and functions of β-catenin. Embo J. 31, 2714–2736 (2012)

Article  PubMed  PubMed Central  CAS  Google Scholar 

M.T. Veeman, J.D. Axelrod, R.T. Moon, A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling. Dev. Cell 5, 367–377 (2003)

Article  PubMed  CAS  Google Scholar 

B. Das, D. Sinha, Diallyl disulphide suppresses the cannonical Wnt signaling pathway and reverses the fibronectin-induced epithelial mesenchymal transition of A549 lung cancer cells. Food Funct. 10, 191–202 (2019)

Article  PubMed  Google Scholar 

N. Aguilera-Montilla, E. Bailón, R. Uceda-Castro, E. Ugarte-Berzal, A. Santos, A. Gutiérrez-González et al. MMP-9 affects gene expression in chronic lymphocytic leukemia revealing CD99 as an MMP-9 target and a novel partner in malignant cell migration/arrest. Oncogene 38, 4605–4619 (2019)

Article  PubMed  CAS  Google Scholar 

M.K. Shi, Y.L. Xuan, X.F. He, FHL1 overexpression as a inhibitor of lung cancer cell invasion via increasing RhoGDIß mRNA expression. Cell J. 24, 239–244 (2022)

PubMed  PubMed Central  Google Scholar 

X. Li, Z. Jia, Y. Shen, H. Ichikawa, J. Jarvik, R.G. Nagele et al. Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate. Cancer Sci. 99, 1326–1333 (2008)

Article  PubMed  CAS  Google Scholar 

A. Sebio, M. Kahn, H.J. Lenz, The potential of targeting Wnt/β-catenin in colon cancer. Expert Opin. Ther. Targets 18, 611–615 (2014)

Article  PubMed  CAS  Google Scholar 

R. Dahmani, P.A. Just, C. Perret, The Wnt/β-catenin pathway as a therapeutic target in human hepatocellular carcinoma. Clin. Res Hepatol. Gastroenterol. 35, 709–713 (2011)

Article  PubMed  CAS  Google Scholar 

T. Hu, C. Li, Convergence between Wnt-β-catenin and EGFR signaling in cancer. Mol. Cancer 9, 236 (2010)

Article  PubMed  PubMed Central  Google Scholar 

L. Chen, F. Qin, X. Deng, J. Avruch, D. Zhou, Hippo pathway in intestinal homeostasis and tumorigenesis. Protein Cell 3, 305–310 (2012)

Article  PubMed  PubMed Central  CAS  Google Scholar 

W. Zheng, M. Yao, M. Wu, J. Yang, D. Yao, L. Wang, Secretory clusterin promotes hepatocellular carcinoma progression by facilitating cancer stem cell properties via AKT/GSK-3β/β-catenin axis. J. Transl. Med. 18, 81 (2020)

Article